Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

Table 3

Responses to eculizumab therapy.

Case	Day	Hb	Platelet	LDH	Cr	Extrarenal complications	Days to normal values*		Days to
		g/L	×10^9/L	U/L	mg/dL		Platelet	LDH	CKD ↓ 1 stage
1	0	83	134	884	1.13	Intermittent confusion, and anasarca	≤7	>21	>21
	7	85	186	965	1.18	Resolved
2	0	98	81	902	3.47	Somnolence, confusion, and vomiting	≤7	70	378, 483
	7	91	162	859	4.45	Resolved
3	0	86	131	1,235	5.12	Headache, confusion, abdominal pain, nausea, and vomiting	≤7	14	63
	7	92	303	672	4.41	Resolved and HTN stabilized
4-1	0	71	105	250	3.79	Anasarca, headache, and visual scotoma	3	14	14
	7	71	198	NA	2.66	Resolved
4-2	0	84	63	770	5.52	Nausea, vomiting, and dyspnea	6	14	14
	6	83	230	321	NA	Resolved
5	0	98	65	693	3.99	Somnolence and intermittent confusion	>84	>84	>84
	7	85	42	818	4.06	No improvement

Since the tests were not performed daily, the actual days may be less than the given values.
CKD: chronic kidney disease.